DuACT: Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19
Study Details
Study Description
Brief Summary
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing. A confirmatory diagnosis of COVID-19 via nasopharyngeal swab, with a positive PCR result within 48 hours of testing.
Consented participants who complete screening and meet study eligibility criteria will be randomized in a 1:1 ratio to receive DuACT or Placebo for 5 days.
Study drugs will be administered BID for 5 days with a loading dose on Day 1. Following randomization, participants will complete a symptom questionnaire, record temperature and record oxygen saturation daily for 10 days and at day 28. A thermometer and pulse oximeter will be provided to each patient at the baseline visit (Day 1).
On study days 3, 6 and 10 participants will have a clinic or home visit by a home healthcare provider. At these visits, a mid-turbinate nasal swab will be obtained, confirmation of the patient's clinical symptoms questionnaire will be completed and any adverse events will be assessed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Arm A: Placebo Placebo administered |
Drug: Placebo
Placebo administered on Days 1-5
|
| Active Comparator: Arm B: Ribavirin/Nitazoxanide (RBV/NTZ) Ribavirin/Nitazoxanide (RBV/NTZ) administered |
Drug: DuACT
Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
|
Outcome Measures
Primary Outcome Measures
- Rate of decline in viral load [10 days]
Rate of decline in viral load over the 10 days after randomization between participants treated with RBV and NTZ for COVID-19 and placebo
Secondary Outcome Measures
- Time to resolution of viral load [28 days]
Time to resolution of viral load, defined by reduction of virus below LLOQ and maintaining it for 2 days.
- Comparison of proportion of subjects who are asymptomatic and symptomatic [10 days]
Comparison of proportion of subjects who are asymptomatic and symptomatic at day 10
- Rate of decline in viral load [Days 3 and 6]
To assess the rate of decline in viral load over days 3 and 6 after randomization
- Change in modified NEWS-2 [28 days]
Assess change in modified National Early Warning System-2 items on a scale of 0 to 20. HIgher scores meaning greater clinical risk.
- Proportion of subjects with treatment emergent adverse events [28 days]
Proportion of subjects with treatment emergent adverse events leading to study drug discontinuation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed a current EC approved informed consent form
-
Male or female participants between 18 and 75 years of age, inclusive diagnosis of SARS-CoV-2 infection, with all of the following, with onset of any within the 72 hours prior to testing:
-
Presence of fever at time of screening of ≥ 38.0°C (≥ 100.0°F) and/or
-
Presence of at least one constitutional symptom associated with Covid-19 (e.g. headache, myalgia, malaise, or fatigue, rash, diarrhea, loss or alteration of taste/smell) of any severity, and/or
-
Presence of at least one respiratory symptom (e.g. cough, chest tightness or sore throat) and/or
-
Diagnosis of COVID-19 with a positive PCR in the past 48 hours
Exclusion Criteria:
-
Pregnant or lactating females
-
Critically ill with presence of one or more of the following signs:
-
difficulty breathing or shortness of breath
-
need for admission to a hospital or an intensive care unit,
-
acute respiratory failure requiring intubation/mechanical ventilation,
-
signs of shock including hypotension
-
Oxygen saturation < 92 %
-
Any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal.
-
Estimated GFR < 50 mL/min/1.73 m2 (calculated using either Modification of Diet in Renal Disease (MDRD) or Cockcroft Gualt
-
Known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia
-
Hemoglobin less than 10 gm/dL or hematocrit < 30 %
-
Retinal eye disease
-
Known chronic kidney disease, stage - 5 or receiving dialysis
-
Inability to tolerate oral medications
-
Allergy or prior adverse reaction to either ribavirin or nitazoxanide
-
QTc interval > 450 mSEC for men and women
-
History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT interval
-
Current treatment with histamine-2 receptor antagonists (H2 blockers) and/or Protein Pump Inhibitors and throughout the study.
-
Have been vaccinated against COVID-19
-
Have participated in a clinical study in the past 30 days
-
Any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sunnyside Office Park | Johannesburg | Gauteng | South Africa |
Sponsors and Collaborators
- University of Witwatersrand, South Africa
- SynaVir
Investigators
- Principal Investigator: Simiso Sokhela, Ezintsha
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DUACT-101